Author: Shapira, Assaf; Benhar, Itai
Title: Toxin-Based Therapeutic Approaches Document date: 2010_10_28
ID: 00cf294x_21
Snippet: Lewis Y (Le Y ), a type 2 blood group related oncofetal carbohydrate antigen is expressed on nearly 70% of human epithelial carcinomas [195] [196] [197] . The LMB-1 immunotoxin consists of the anti-Lewis Y monoclonal antibody B3 [198] conjugated to PE38. In a Phase I clinical trial, the immunotoxin was tested on 38 patients with Le Y expressing carcinomas of breast, ovarian, colon, esophagus, stomach and ampulla of Vater. A complete remission was.....
Document: Lewis Y (Le Y ), a type 2 blood group related oncofetal carbohydrate antigen is expressed on nearly 70% of human epithelial carcinomas [195] [196] [197] . The LMB-1 immunotoxin consists of the anti-Lewis Y monoclonal antibody B3 [198] conjugated to PE38. In a Phase I clinical trial, the immunotoxin was tested on 38 patients with Le Y expressing carcinomas of breast, ovarian, colon, esophagus, stomach and ampulla of Vater. A complete remission was observed in a patient with metastatic breast cancer and a greater than 75% tumor reduction was observed in a colon cancer patient following systemic administration of the immunotoxin. The major toxicity was vascular leak syndrome ascribed to endothelial damage, probably due to binding of the B3 antibody to Le Y antigen which is present in small amounts on endothelial cells [199] . Later developments of Lewis Y targeted toxins produced the recombinant immunotoxins B3(Fv)-PE38 (LMB-7), B3(dsFv)-PE38 (LMB-9) and BR96-Fv-PE40 (SGN-10) which were clinically evaluated in patients with Lewis Y-expressing malignancies. However, no significant antitumor activity was observed in these trials [10, 200] .
Search related documents:
Co phrase search for related documents- antitumor activity and clinical trial: 1, 2, 3, 4, 5
- antitumor activity and colon cancer: 1
- antitumor activity and complete remission: 1
- antitumor activity and endothelial cell: 1
- antitumor activity and metastatic breast cancer: 1
- antitumor activity and significant antitumor activity: 1, 2, 3, 4
- antitumor activity and systemic administration: 1
- antitumor activity and tumor reduction: 1
- blood group and breast cancer: 1
- blood group and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- blood group and endothelial cell: 1, 2, 3
- blood group and small amount: 1
- breast cancer and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58
- breast cancer and colon cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56
- breast cancer and complete remission: 1, 2, 3
- breast cancer and endothelial cell: 1, 2
- breast cancer and major toxicity: 1, 2
- breast cancer and metastatic breast cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- breast cancer and metastatic breast cancer patient: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date